|
Drug/s | Reference/s | Year | Target | Study types | Cell lines/animal model | Effects |
|
15-deoxy-PGJ2 | [11–16] | 2001, 2003, 2004 | PPAR-γ | In vitro | NB cell lines and primary cultures of cortical neurons | Inhibition of growth and apoptosis induction, through PPAR-γ-dependent and PPAR-γ-independent effects. |
|
GW1929 | [11] | 2001 | PPAR-γ | In vitro | LA-N-5 | Prodifferentiating effect and inhibition of proliferation. |
|
Rosiglitazone and 15-deoxy-PGJ2 | [12] | 2004 | PPAR-γ | In vitro | SH-SY5Y, SH-EP1, SK-N-AS, SK-N-FI, LA-N-5, SMS-KCNR, SK-N-DZ, and LA-N-1 | Inhibition of cell growth with different sensitivity related to the cell phenotype. |
|
Ciglitazone and 15-deoxy-PGJ2 | [13] | 2004 | PPAR-γ | In vitro | SK-N-AS, IMR-32, SK-N-SH, and ND-7 | Overexpression of Rb protein and inhibition of PPAR-γ activity, reducing NB cell growth. |
|
Ciglitazone, pioglitazone, troglitazone, and rosiglitazone | [17] | 2005 | PPAR-γ | In vitro | Kelly, LA-N-1, LA-N-5, LS, IMR-32, SK-N-SH, and SH-SY5Y | Inhibition of cell proliferation and viability in a dose-dependent manner. |
|
Rosiglitazone | [18] | 2010 | PPAR-γ | In vivo | SK-N-SH xenograft NB mouse model | Inhibition of tumor growth. |
|
Troglitazone | [19] | 2002 | PPAR-γ | In vitro | NB-1 cell line | Increase of PPAR-γ-dependent apoptosis. |
|
Troglitazone | [20] | 2006 | PPAR-γ | In vitro | SHEP NB cell line | Increase of PPAR-γ-dependent apoptosis. |
|
Rosiglitazone | [21, 22] | 2006, 2007 | PPAR-γ | In vitro | SH-SY5Y cell line | Antiapoptotic effects of rosiglitazone which protected NB cells subjected to MPP+-induced mitochondrial injury reducing ROS production. |
|
Rosiglitazone | [23] | 2006 | PPAR-γ | In vitro | SK-N-AS and SH-SY5Y cell lines | Inhibition of cell adhesion, invasiveness, and proapoptotic effects. |
|
Rosiglitazone | [24] | 2010 | PPAR-γ | In vivo | SK-N-AS xenograft NB mouse model | Significant decrease of tumor growth (−70%) as compared to control mice. |
|
Rosiglitazone | [25] | 2008 | PPAR-γ | In vitro | Rat primary cortical neurons | Induction of cell differentiation, increasing dendritic spine density. |
|
Pioglitazone and rosiglitazone | [26] | 2011 | PPAR-γ | Both in vitro and in vivo | Adult male Wistar rats | Induction of proliferation, differentiation, and migration of neural stem cells in vitro and in vivo. |
|
Pioglitazone | [27] | 2009 | PPAR-γ | In vitro | SH-SY5Y cell line | Induction of differentiation and neurite outgrowth, promoting differentiation and outgrowth of cell processes. |
|
Rosiglitazone | [28] | 2014 | PPAR-γ | In vitro | Mouse NB Neuro 2a (N2A) cell line | Stimulation of neurite outgrowth and significant increase of the population of neurite-bearing cells, via PPAR-γ pathway. |
|
Oleic acid or GW0742 | [29] | 2007 | PPAR-β/δ | In vitro | SH-NH-5YSY cell line | Induction of G1 cell cycle arrest, reduction of cell migration and invasiveness, and an increase of neuronal differentiation. |
|